Filing Flows › Kura Oncology (KURA) › Q4 2025
Kura Oncology (KURA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Kura Oncology (KURA) reported revenue of $17.3M for the fourth quarter 2025 (Q4 2025) and -16% from the quarter before. Operating margin was -497.6%, net loss $81.0M (467.2% of revenue).
Kura Oncology, Q4 2025: revenue $17.3M, operating margin -497.6%, net loss $81.0M, operating cash flow $117M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.3M | -16% | — |
| Operating profit | −$86.3M | — | — |
| Net earnings | −$81.0M | — | — |
| Operating cash flow | $117M | — | — |
| Free cash flow | $115M | — | — |
What changed
Revenue was $17.3M in Q4 2025, down 16% from the previous quarter.
Operating costs exceeded revenue by $86.3M, an operating margin of -497.6%. The quarter ended with a net loss of $81.0M, wider than the previous quarter's $74.1M loss.
Operating cash flow was $117.3M. Non-cash charges added back $403K of depreciation and $11.4M of share-based compensation. Working capital and other items added $186.5M. Capital expenditures of $2.3M left free cash flow of $115.0M.
Questions
What was Kura Oncology's revenue in the fourth quarter 2025?
Kura Oncology (KURA) reported revenue of $17.3M for the fourth quarter 2025 (Q4 2025) and -16% from the quarter before.
Was Kura Oncology profitable in the fourth quarter 2025?
Operating loss was $86.3M (-497.6% of revenue) and net loss $81.0M.
Source: Kura Oncology 10-K on SEC EDGAR.